Clazakizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name

Clazakizumab

Accession Number

DB12849

Description

Clazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis.

Type

Biotech

Groups

Investigational

Biologic Classification

Protein Based Therapies
Monoclonal antibody (mAb)

Protein Chemical Formula

Not Available

Protein Average Weight

Not Available

Sequences

Not Available

Synonyms

BMS-945429

Pharmacology

Indication: Not Available
Contraindications & Blackbox Warnings: Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Learn about our commercial Adverse Effects data.
Learn More
Toxicity: Not Available
Affected organisms: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Unlock Additional Data
Abciximab	The risk or severity of adverse effects can be increased when Abciximab is combined with Clazakizumab.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Clazakizumab.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Clazakizumab.
Alirocumab	The risk or severity of adverse effects can be increased when Alirocumab is combined with Clazakizumab.
Ansuvimab	The risk or severity of adverse effects can be increased when Clazakizumab is combined with Ansuvimab.
Anthrax immune globulin human	The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Clazakizumab.
Antilymphocyte immunoglobulin (horse)	The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Clazakizumab.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Clazakizumab.
Asfotase alfa	The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Clazakizumab.
Atezolizumab	The risk or severity of adverse effects can be increased when Atezolizumab is combined with Clazakizumab.

Additional Data Available

Extended Description

Available for Purchase

Extended description of the mechanism of action and particular properties of each drug interaction.

Learn more

Severity

Available for Purchase

A severity rating for each drug interaction, from minor to major.

Learn more

Evidence Level

Available for Purchase

A rating for the strength of the evidence supporting each drug interaction.

Learn more

Action

Available for Purchase

An effect category for each drug interaction. Know how this interaction affects the subject drug.

Learn more

Food Interactions

Not Available

Chemical Identifiers

UNII: 4S38Z8RA9O
CAS number: 1236278-28-6

References

General References

Not Available

External Links

PubChem Substance: 347911396
Wikipedia: Clazakizumab

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
3	Recruiting	Treatment	Antibody-mediated Rejection	1
2	Active Not Recruiting	Treatment	Coronavirus Disease 2019 (COVID‑19)	2
2	Completed	Treatment	Antibody-mediated Rejection	1
2	Completed	Treatment	Psoriatic Arthritis	1
2	Completed	Treatment	Rheumatoid Arthritis	2
2	Enrolling by Invitation	Treatment	Coronavirus Disease 2019 (COVID‑19) / Respiratory Failure	1
2	Not Yet Recruiting	Treatment	Coronavirus Disease 2019 (COVID‑19)	1
2	Recruiting	Treatment	Asthma	1
2	Recruiting	Treatment	Coronavirus Disease 2019 (COVID‑19)	1
2	Recruiting	Treatment	Coronavirus Disease 2019 (COVID‑19) / Covid-19 Infection	1